Clinical Center of Vojvodina, Clinic for Maxillofacial and Oral Surgery, Novi Sad, Serbia; Faculty of Medicine, Department for Dentistry and Maxillofacial Surgery, University of Novi Sad, Novi Sad, Serbia.
Clinical Center of Vojvodina, Clinic for Maxillofacial and Oral Surgery, Novi Sad, Serbia; Faculty of Medicine, Department for Dentistry and Maxillofacial Surgery, University of Novi Sad, Novi Sad, Serbia.
J Stomatol Oral Maxillofac Surg. 2023 Dec;124(6):101462. doi: 10.1016/j.jormas.2023.101462. Epub 2023 Mar 30.
Aim of this study was to explore the survival predictive factors and treatment outcomes in a cohort of SGC patients treated at a single center over a period of 25 years.
Patients who had received primary treatment for SGC were enroled. Outcomes evaluated were: overall survival (OS), disease specific survival (DSS), recurrence free survival (RFS), locoregional recurrence free survival (LRFS) and distant metastasis free survival (DFS).
A total of 40 patients with SGC were enroled in the study. The most common tumor was the adenoid cystic carcinoma (60% of cases). Cumulative OS for 5-and 10-year follow up period was 81% and 60%, respectively. Thirteen patients (32.5%) developed distant metastases during follow-up. Nodal status, high-grade histology, tumor stage and adjuvant radiation-therapy (RT) were significant variables on multivariate analysis for survival and treatment outcomes.
Submandibular gland carcinomas represent rare and heterogenous tumor group regarding histological appearance and locoregional and distant metastatic potential. Tumor histological grade, AJCC tumor stage and nodal status were the strongest predictive factors for survival and treatment outcomes. RT improved OS and locoregional treatment outcome, but not DFS. Elective neck dissection (END) could be beneficial for selected cases of SGC. Superselective neck dissection of levels I-IIa may be the level of dissection for END. Distant metastases were the main cause of death and treatment failure. Prognostic factors for poor DMFS were AJCC stage III and IV, high tumor grade and nodal status.
本研究旨在探讨在单一中心 25 年的治疗期间,一组 SGC 患者的生存预测因素和治疗结果。
招募了接受 SGC 初始治疗的患者。评估的结果是:总生存(OS)、疾病特异性生存(DSS)、无复发生存(RFS)、局部区域无复发生存(LRFS)和无远处转移生存(DFS)。
本研究共纳入 40 例 SGC 患者。最常见的肿瘤是腺样囊性癌(60%的病例)。5 年和 10 年随访期间的累积 OS 分别为 81%和 60%。13 例患者(32.5%)在随访期间发生远处转移。多因素分析显示,淋巴结状态、高级别组织学、肿瘤分期和辅助放疗(RT)是生存和治疗结果的显著变量。
下颌下腺腺癌在组织学表现以及局部和远处转移潜能方面是罕见的异质性肿瘤群体。肿瘤组织学分级、AJCC 肿瘤分期和淋巴结状态是生存和治疗结果的最强预测因素。RT 改善了 OS 和局部区域治疗结果,但不能改善 DFS。选择性颈部清扫术(END)可能对某些 SGC 病例有益。I-IIa 水平的超选择性颈部清扫术可能是 END 的清扫水平。远处转移是死亡和治疗失败的主要原因。不良 DMFS 的预测因素是 AJCC 分期 III 和 IV、高肿瘤分级和淋巴结状态。